help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jordan, V. C.
Right arrow Articles by Allen, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jordan, V. C.
Right arrow Articles by Allen, K. E.

Endocrinology, Vol 108, 1353-1361, Copyright © 1981 by Endocrine Society


ARTICLES

Geometric isomers of substituted triphenylethylenes and antiestrogen action

VC Jordan, B Haldemann and KE Allen

The estrogenic and antiestrogenic activities of tamoxifen ICI 47,699, enclomiphene, zuclomiphene, and the geometric isomers of monohydroxytamoxifen and CI628 were determined in the 3-day immature rat uterine weight test. Tamoxifen, enclomiphene, and the releated geometric isomers of monohydroxytamoxifen and CI628 were partially estrogenic with antiestrogenic properties. ICI 47,699 and zuclomiphene were predominantly estrogenic; however, an antiestrogen effect for zuclomiphene (100 micrograms daily) was demonstrable and large doses of ICI 47,699 (1 or 10 mg daily) inhibited full estrogen action. In contrast, the geometric isomers of monohydroxytamoxifen and CI628 related to ICI 47,699 and zuclomiphene were partially estrogenic with antiestrogenic properties. The estrogenic properties of ICI 47,699 were classified in three ways: elevation of uterine wet weight, increase in whole uterine DNA, and increase in the mitotic activity of luminal epithelial cells. In general, ICI 47,699 was able to initiate estrogenic responses of DNA synthesis or mitosis by translocation of fewer cytoplasmic estrogen receptors to the nuclear compartment than tamoxifen. A model is proposed to explain antiestrogen action in terms of the geometric requirements for receptor binding. It is suggested that the position in space of the alkylaminoethoxyside chain is of fundamental importance. Overall, these data lend support to the view that a structurally specific ligand-estrogen receptor complex can influence the future events within a target tissue to produce either an agonist or an antagonist response.


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
Y. Zheng, D. Sun, A. K. Sharma, G. Chen, S. Amin, and P. Lazarus
Elimination of Antiestrogenic Effects of Active Tamoxifen Metabolites by Glucuronidation
Drug Metab. Dispos., October 1, 2007; 35(10): 1942 - 1948.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
J. I. Macgregor and V. C. Jordan
Basic Guide to the Mechanisms of Antiestrogen Action
Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1981 by The Endocrine Society